|
Tideglusib市场分析报告
|
Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2022 ... GSK3) Inhibitor Emerging Drugs Tideglusib: AMO Pharma Tideglusib is an orally available, small- ... GSK3-?), a widely studied tau kinase. Tideglusib is a non-ATP competitive inhibitor of ... BCN Biosciences HitGen Key Products Tideglusib 9 ING 41 Anatabine BCN-057 ...
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2018 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2018 SUMMARY Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or ...
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H1 2018 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H1 2018 SUMMARY Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or ...
Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2019 Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2019 SUMMARY According to the recently published report 'Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2019'; Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or ...
Myotonic Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major myotonic dystrophy markets reached a value of US$ 96.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 260.4 Million by 2034, exhibiting a growth rate (CAGR) of 9.45% during 2024-2034. The myotonic dystrophy market ...
Dental Fillings Market Size, Share & Trends Analysis Report By Filling Type (Direct, Indirect), By Region (North America, Asia Pacific, Europe, Latin America, Middle East & Africa), And Segment Forecasts, 2025 - 2030 ... . Scientists have discovered a drug called Tideglusib, for the treatment of Alzheimer’s disease ...
|
|
|